Immunis.AI Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $32.2M

  • Investors
  • 3

Immunis.AI General Information

Description

Developer of a non-invasive blood-based immunogenomic platform discovery platform designed to detect cancer. The company's platform uses machine learning to perform detailed genomic analysis of patient blood samples to understand diseases by analyzing differential gene expression patterns to characterize the disease and identify novel biomarkers and biological pathways, helping clinicians and pharmaceutical developers to improve sensitive small tumor profiling and detect diseases that individuals may be harboring and the body's immune response to those diseases.

Contact Information

Website
immunis.ai
Formerly Known As
OncoCell MDx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1310 North Stephenson Highway
  • Suite 101
  • Royal Oak, MI 48067
  • United States
+1 (248)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Corporate Office
  • 1310 North Stephenson Highway
  • Suite 101
  • Royal Oak, MI 48067
  • United States
+1 (248)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunis.AI Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 01-Oct-2021 $32.2M Completed Product Development
2. Early Stage VC (Series A) 15-Aug-2012 Completed Startup
1. University Spin-Out 01-Jun-2011 Completed Startup
To view Immunis.AI’s complete valuation and funding history, request access »

Immunis.AI Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-2
Series A-1 49,949,886 $0.000100 $0.12 $0.12 1x $0.12 18.71%
To view Immunis.AI’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Immunis.AI Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a non-invasive blood-based immunogenomic platform discovery platform designed to detect cancer. The company
Discovery Tools (Healthcare)
Royal Oak, MI
10 As of 2021

Menlo Park, CA
 

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunis.AI Competitors (5)

One of Immunis.AI’s 5 competitors is GRAIL, a Formerly VC-backed company based in Menlo Park, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GRAIL Formerly VC-backed Menlo Park, CA
Exact Sciences Formerly VC-backed Madison, WI
Adaptive Biotechnologies Formerly VC-backed Seattle, WA
Myriad Genetics Corporation Salt Lake City, UT
MDxHealth Formerly VC-backed Liège, Belgium
You’re viewing 5 of 5 competitors. Get the full list »

Immunis.AI Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunis.AI Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Savitr Capital Venture Capital Minority
Remiges Ventures Venture Capital Minority
Harvard University University
To view Immunis.AI’s complete investors history, request access »

Immunis.AI FAQs

  • When was Immunis.AI founded?

    Immunis.AI was founded in 2011.

  • Where is Immunis.AI headquartered?

    Immunis.AI is headquartered in Royal Oak, MI.

  • What is the size of Immunis.AI?

    Immunis.AI has 10 total employees.

  • What industry is Immunis.AI in?

    Immunis.AI’s primary industry is Discovery Tools (Healthcare).

  • Is Immunis.AI a private or public company?

    Immunis.AI is a Private company.

  • What is the current valuation of Immunis.AI?

    The current valuation of Immunis.AI is .

  • What is Immunis.AI’s current revenue?

    The current revenue for Immunis.AI is .

  • How much funding has Immunis.AI raised over time?

    Immunis.AI has raised $42.2M.

  • Who are Immunis.AI’s investors?

    Savitr Capital, Remiges Ventures, and Harvard University have invested in Immunis.AI.

  • Who are Immunis.AI’s competitors?

    GRAIL, Exact Sciences, Adaptive Biotechnologies, Myriad Genetics, and MDxHealth are competitors of Immunis.AI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process